MedKairos is automating the cancer biopsy assessment process. 1 out of every 5 biopsies taken fail to collect adequate tissue samples to come to a diagnosis. We are a medical technology company building the Bioptic™ system to increase the accuracy of cancer sample collection and reduce the time and labor required to reach a diagnosis. MedKairos has developed the Bioptic platform to verify sample quality at the point of care to make sure that patients will only have to undergo a biopsy procedure once. Bioptic™ uses a proprietary cartridge, camera, and image processing software package to verify that a sample has enough tissue to make a diagnosis - work traditionally done by a pathologist and a microscope.
Michael Moore founded MedKairos to address challenges that he saw throughout his medical education at the University of Michigan. Prior to entering the time constraints of residency, he decided to take a leave from his medical training to develop this venture full time and, ultimately, have a global impact on patient care.